Metamizol Kalceks

Metamizole, the active ingredient in Metamizol Kalceks, is a pyrazolone derivative presented as an injectable solution for intramuscular and intravenous use. It treats acute pain, post‑operative pain, fever and colic in adult patients.

GNH USA supplies Metamizol Kalceks as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metamizole is used to manage pain and fever through inhibition of prostaglandin synthesis.

Acute pain: provides rapid analgesia for severe short‑term pain. Post‑operative pain: reduces discomfort after surgical procedures. Fever: lowers elevated body temperature in febrile states. Colic: relieves visceral pain associated with gastrointestinal colic.

Metamizole may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Hypotension: transient drop in blood pressure after injection. - Nausea: feeling of queasiness or upset stomach. - Vomiting: expulsion of stomach contents. - Injection site reactions: pain, redness or swelling at the administration site.

Serious or Rare Side Effects: - Agranulocytosis: severe reduction in white blood cells, increasing infection risk. - Anaphylaxis: life‑threatening allergic reaction with airway compromise. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Blood dyscrasias: abnormal blood cell counts beyond agranulocytosis. - Severe hypotension: marked blood pressure fall requiring medical intervention.

When using Metamizol Kalceks, clinicians should observe several safety measures.

Assess renal and hepatic function: adjust use if organ impairment is present. Monitor blood counts: watch for early signs of agranulocytosis. Use with caution in patients with known hypersensitivity to pyrazolones. Avoid in individuals with a history of severe blood dyscrasias. Adjust dosing in elderly patients: consider reduced volume or slower administration. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Metamizole can interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Myelosuppressive agents: combined use may exacerbate bone‑marrow suppression. - ACE inhibitors: concurrent use can potentiate hypotensive effects. - Anticoagulants: may increase bleeding risk due to platelet function changes.

Moderate Interactions (Monitor Closely): - NSAIDs: additive gastrointestinal irritation and renal stress. - Diuretics: potential for enhanced electrolyte disturbances. - CYP450 substrates: may alter metabolism of certain drugs, requiring monitoring.